Announcement • Mar 17
Rekvina Laboratories Limited (BSE:526075) entered into agreement to acquire Radiant Parenterals Limited from Surbhit Mukesh Shah, Amit Mukesh Shah, Dhruvalkumar Patel, Krima Surbhit Shah and Ami Amit Shah for approximately INR 140 million. Rekvina Laboratories Limited (BSE:526075) entered into agreement to acquire Radiant Parenterals Limited from Surbhit Mukesh Shah, Amit Mukesh Shah, Dhruvalkumar Patel, Krima Surbhit Shah and Ami Amit Shah for approximately INR 140 million on March 16, 2026. For the period ended March 31, 2025 Radiant Parenterals Limited reported Revenue of INR 316.7 million.
The transaction is subject to approval of offer by acquirer shareholders, approval by regulatory board / committee, approval of offer by acquirer board and subject to statutory approval. The deal has been approved by the board. Announcement • Jan 29
Rekvina Laboratories Limited to Report Q3, 2026 Results on Feb 06, 2026 Rekvina Laboratories Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 06, 2026 Board Change • Jan 16
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. MD, CEO & Executive Director Amit Shah is the most experienced director on the board, commencing their role in 2000. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.